<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02539576</url>
  </required_header>
  <id_info>
    <org_study_id>204662</org_study_id>
    <nct_id>NCT02539576</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects</brief_title>
  <official_title>A Phase I, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Abacavir/Dolutegravir/Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) 600 milligrams (mg)/50 mg/300 mg&#xD;
      fixed-dose combination (FDC) tablet is currently approved in the United States (US) and&#xD;
      Europe. Although the pharmacokinetics (PK), safety and tolerability of ABC/DTG/3TC FDC&#xD;
      tablets have been extensively studied in subjects not of Japanese heritage, these parameters&#xD;
      have not been exclusively assessed in Japanese subjects. To support the marketing application&#xD;
      in Japan, this single-dose, open-label study will characterize the PK, safety and&#xD;
      tolerability of ABC/DTG/3TC FDC tablet in adult Japanese healthy subjects. A maximum of 12&#xD;
      subjects will be enrolled such that approximately 10 evaluable subjects complete the study.&#xD;
      The study will consist of a screening, treatment phase (single oral dose under the fasted&#xD;
      state) and follow-up visit (within 7-14 days of the last PK sample collected). The total&#xD;
      duration of the study for each subject will be approximately up to 48 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero (pre-dose) to time of last quantifiable concentration (AUC[0-t]) following a single oral dose administration of ABC/DTG/3TC 600 mg/ 50 mg/ 300 mg FDC tablet in healthy, adult Japanese subjects</measure>
    <time_frame>Day 1: Pre-dose and at 30 minutes, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 h post dose.</time_frame>
    <description>Blood samples for PK analyses will be collected at pre-dose and 30 minutes, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post- dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC[0-infinity]) following a single oral dose administration of ABC/DTG/3TC 600 mg/ 50 mg/ 300 mg FDC tablet in healthy, adult Japanese subjects</measure>
    <time_frame>Day 1: Pre-dose and at 30 minutes, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 h post dose.</time_frame>
    <description>Blood samples for PK analyses will be collected at pre-dose and 30 minutes, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post- dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) following a single oral dose administration of ABC/DTG/3TC 600 mg/ 50 mg/ 300 mg FDC tablet in healthy, adult Japanese subjects</measure>
    <time_frame>Day 1: Pre-dose and at 30 minutes, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 h post dose.</time_frame>
    <description>Blood samples for PK analyses will be collected at pre-dose and 30 minutes, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post- dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of occurrence of Cmax (tmax) following a single oral dose administration of ABC/DTG/3TC 600 mg/ 50 mg/ 300 mg FDC tablet in healthy, adult Japanese subjects</measure>
    <time_frame>Day 1: Pre-dose and at 30 minutes, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 h post dose.</time_frame>
    <description>Blood samples for PK analyses will be collected at pre-dose and 30 minutes, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post- dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration at 24 h after dose administration (C24) following a single oral dose administration of ABC/DTG/3TC 600 mg/ 50 mg/ 300 mg FDC tablet in healthy, adult Japanese subjects</measure>
    <time_frame>Day 1: Pre-dose and at 30 minutes, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 h post dose.</time_frame>
    <description>Blood samples for PK analyses will be collected at pre-dose and 30 minutes, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post- dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase half-time (t1/2) following a single oral dose administration of ABC/DTG/3TC 600 mg/ 50 mg/ 300 mg FDC tablet in healthy, adult Japanese subjects</measure>
    <time_frame>Day 1: Pre-dose and at 30 minutes, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 h post dose.</time_frame>
    <description>Blood samples for PK analyses will be collected at pre-dose and 30 minutes, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post- dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance following oral dosing (CL/F) following a single oral dose administration of ABC/DTG/3TC 600 mg/ 50 mg/ 300 mg FDC tablet in healthy, adult Japanese subjects</measure>
    <time_frame>Day 1: Pre-dose and at 30 minutes, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 h post dose.</time_frame>
    <description>Blood samples for PK analyses will be collected at pre-dose and 30 minutes, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post- dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of AUC(0-infinity) obtained by extrapolation (%AUCex) following a single oral dose administration of ABC/DTG/3TC 600 mg/ 50 mg/ 300 mg FDC tablet in healthy, adult Japanese subjects</measure>
    <time_frame>Day 1: Pre-dose and at 30 minutes, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 h post dose.</time_frame>
    <description>Blood samples for PK analyses will be collected at pre-dose and 30 minutes, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post- dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase rate constant (Lambda-z) following a single oral dose administration of ABC/DTG/3TC 600 mg/ 50 mg/ 300 mg FDC tablet in healthy, adult Japanese subjects</measure>
    <time_frame>Day 1: Pre-dose and at 30 minutes, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 h post dose.</time_frame>
    <description>Blood samples for PK analyses will be collected at pre-dose and 30 minutes, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post- dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by the number of subjects with adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>From Day-1 up to follow-up (approx. Day 18)</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values for composite of clinical chemistry parameters as a safety measure</measure>
    <time_frame>Day-1 and follow-up (approx. Day 18)</time_frame>
    <description>Clinical chemistry parameters includes blood urea nitrogen, potassium, aspartate aminotransferase, total and direct bilirubin, creatinine, sodium, alanine aminotransferase, total protein, glucose, calcium, alkaline phosphatase and albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline values for composite of clinical chemistry parameters as a safety measure</measure>
    <time_frame>Day-1 and follow-up (approx. Day 18)</time_frame>
    <description>Clinical chemistry parameters includes blood urea nitrogen, potassium, aspartate aminotransferase, total and direct bilirubin, creatinine, sodium, alanine aminotransferase, total protein, glucose, calcium, alkaline phosphatase and albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis assessments</measure>
    <time_frame>Day-1 and follow-up (approx. Day 18)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by systolic and diastolic blood pressure measurements</measure>
    <time_frame>Day-1, pre-dose and at 4 h, 24 h, 48 h post-dose, and follow-up (approx. Day 18)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by pulse rate measurements</measure>
    <time_frame>Day-1, pre-dose and at 4 h, 24 h, 48 h post-dose, and follow-up (approx. Day 18)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Day-1 and follow-up (approx. Day 18)</time_frame>
    <description>Single 12-lead ECG will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT correction using Fridericia's Formula (QTcF) intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values for composite of clinical haematology parameters as a safety measure</measure>
    <time_frame>Day-1 and follow-up (approx. Day 18)</time_frame>
    <description>Clinical haematology parameters includes platelet count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline values for composite of clinical haematology parameters as a safety measure</measure>
    <time_frame>Day-1 and follow-up (approx. Day 18)</time_frame>
    <description>Clinical haematology parameters includes platelet count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>ABC/DTG/3TC FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive treatment with a single oral dose of ABC 600 mg/DTG 50 mg/3TC 300 mg FDC tablet administered under the fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABC/DTG/3TC FDC tablet</intervention_name>
    <description>ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with &quot;572 TrÄ±&quot; on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally.</description>
    <arm_group_label>ABC/DTG/3TC FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 18 and 55 years of age inclusive, at the time of signing the informed consent.&#xD;
&#xD;
          -  Japanese subjects who were born in Japan with 4 ethnic Japanese grand parents and must&#xD;
             not have lived outside Japan for more than 10 years with being a Japanese passport&#xD;
             holder (current or expired).&#xD;
&#xD;
          -  Healthy as determined by the investigator or medically qualified designee based on a&#xD;
             medical evaluation including medical history, physical examination, and laboratory&#xD;
             tests.&#xD;
&#xD;
          -  Subject values for haematology and chemistry within the normal range. A subject with a&#xD;
             clinical abnormality or laboratory parameter(s) which is/are not specifically listed&#xD;
             in the inclusion or exclusion criteria, outside the reference range for the population&#xD;
             being studied may be included only if the investigator documents that the finding is&#xD;
             unlikely to introduce additional risk factors and will not interfere with the study&#xD;
             procedures.&#xD;
&#xD;
          -  Body weight &gt;=50 kilograms (kg) (110 pounds [lbs]) for men and &gt;=45 kg (99 lbs) for&#xD;
             women and body mass index (BMI) within the range 18.5-31.0 kilogram per meter square&#xD;
             (kg/m^2) (inclusive).&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Females- A female subject is eligible to participate if she is not pregnant (as confirmed&#xD;
        by a negative serum or urine [according to the sites standard of practice] human chorionic&#xD;
        gonadotrophin [hCG] test), not lactating, and at least one of the following conditions&#xD;
        applies:&#xD;
&#xD;
          1. Non-reproductive potential defined as: pre-menopausal females with one of the&#xD;
             following: Documented tubal ligation Documented hysteroscopic tubal occlusion&#xD;
             procedure with follow-up confirmation of bilateral tubal occlusion Hysterectomy&#xD;
             Documented bilateral oophorectomy; Postmenopausal defined as 12 months of spontaneous&#xD;
             amenorrhea (in questionable cases a blood sample with simultaneous follicle&#xD;
             stimulating hormone [FSH] and estradiol levels consistent with menopause). Females on&#xD;
             hormone replacement therapy (HRT) and whose menopausal status is in doubt will be&#xD;
             required to use one of the highly effective contraception methods if they wish to&#xD;
             continue their HRT during the study. Otherwise, they must discontinue HRT to allow&#xD;
             confirmation of post-menopausal status prior to study enrolment.&#xD;
&#xD;
          2. Reproductive potential and agrees to follow one of the options listed below in the&#xD;
             modified list of highly effective methods for avoiding pregnancy in females of&#xD;
             reproductive potential (FRP) from 30 days prior to the first dose of study medication&#xD;
             and until 2 weeks after dosing with study medication and completion of the follow-up&#xD;
             visit.&#xD;
&#xD;
        The investigator is responsible for ensuring that subjects understand how to properly use&#xD;
        these methods of contraception.&#xD;
&#xD;
          -  Capable of giving signed informed consent as described in the protocol which includes&#xD;
             compliance with the requirements and restrictions listed in the consent form and in&#xD;
             the protocol.&#xD;
&#xD;
          -  Documentation that the subject is negative for the human leukocyte antigen (HLA)&#xD;
             B*5701 allele.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &gt;1.5x upper limit of normal (ULN) (isolated bilirubin&#xD;
             &gt;1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  QTcF &gt;450 millisecond (msec)&#xD;
&#xD;
        NOTES:&#xD;
&#xD;
        The QT duration corrected for heart rate (QTc) is the QTcF machine-read or manually&#xD;
        over-read.&#xD;
&#xD;
        The specific formula that will be used to determine eligibility and discontinuation for an&#xD;
        individual subject should be determined prior to initiation of the study. In other words,&#xD;
        several different formulae cannot be used to calculate the QTc for an individual subject&#xD;
        and then the lowest QTc value used to include or discontinue the subject from the trial.&#xD;
&#xD;
        For purposes of data analysis, QT interval corrected for heart rate using Bazett's formula&#xD;
        (QTcB), QTcF, another QT correction formula, or a composite of available values of QTc will&#xD;
        be used as specified in the reporting and analysis plan (RAP).&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drugs, including&#xD;
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or&#xD;
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication, unless in the opinion of the&#xD;
             investigator and GlaxoSmithKline (GSK) medical monitor the medication will not&#xD;
             interfere with the study procedures or compromise subject safety.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as: an&#xD;
             average weekly intake of &gt;14 drinks for males or &gt;7 drinks for females. One unit is&#xD;
             equivalent to 12 gram (g) of alcohol: 12 ounces (360 milliliter [mL]) of beer, 5&#xD;
             ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or medical&#xD;
             monitor, contraindicates their participation.&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test&#xD;
             result at screening or within 3 months prior to first dose of study treatment.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood product in&#xD;
             excess of 500 mL within 56 days&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2015</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>Abacavir/dolutegravir/lamivudine</keyword>
  <keyword>Japanese</keyword>
  <keyword>Fixed-dose combination</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

